The legal action underscores InMode’s commitment to protecting consumer safety and enforcing its trademark rights. The injunction effectively freezes the assets of the defendants and puts a stop to the listing and sale of counterfeit Morpheus8 devices, which utilize InMode’s proprietary radiofrequency technology. With a market capitalization of nearly $1 billion and currently trading near its 52-week low, InvestingPro analysis suggests the stock may be undervalued, presenting an interesting opportunity for investors looking at companies with strong intellectual property protection.
InMode’s CEO, Moshe Mizrahy, emphasized the company’s zero-tolerance stance on counterfeit goods and fraudulent business practices. "We are committed to public safety and will continue to protect consumers from potential harm caused by unauthorized Morpheus8 devices," Mizrahy stated.
To further safeguard patients and ensure the use of genuine products, InMode has introduced a Verified Provider Program specifically for its Morpheus8 technology. This program allows certified clinics to demonstrate their use of authentic InMode technology, aiding patients in identifying safe and authorized providers. Consumers in the United States and Canada can utilize the "Find a Provider" tool on InMode’s website to locate approved practitioners.
InMode is recognized for its innovative medical technologies, particularly its novel radiofrequency (RF) technology, which is used in a variety of medical specialties including plastic surgery, dermatology, and gynecology. The company’s efforts to combat counterfeit sales are part of its broader initiative to ensure the delivery of high-quality, trusted medical treatments to patients.
The court’s decision in favor of InMode sends a clear message to counterfeiters and reinforces the legal protections available to medical technology companies. This news is based on a press release statement from InMode Ltd. The company’s financial health score of "GREAT" on InvestingPro, along with its strong cash flow position and robust current ratio of 8.73, indicates solid operational execution alongside its legal victories. Discover more insights about InMode and access comprehensive analysis of 1,400+ stocks through InvestingPro’s detailed research reports.chat
In other recent news, InMode Ltd. reported preliminary first-quarter revenues of $77.2 million to $77.5 million, which fell short of consensus estimates. Despite this, the company maintained its full-year 2025 revenue guidance of $395 million to $405 million. However, analysts have expressed varying opinions on InMode’s prospects. Jefferies upgraded the stock from Hold to Buy, albeit with a reduced price target of $15, citing a cautiously optimistic long-term outlook. Conversely, BTIG downgraded the stock from Buy to Neutral, highlighting challenges in the medical aesthetics market and concerns about the company’s ability to meet its revenue guidance. Canaccord Genuity also adjusted its outlook, lowering the price target to $15 while maintaining a Hold rating, pointing to economic headwinds and a history of guidance revisions. InMode has acknowledged the potential need to revise its revenue guidance if improvements are not seen in the coming months. The company is also dealing with declining margins and increased costs due to its strategy to expand commercial teams. These developments underscore the challenges InMode faces in the current economic climate.
Source: https://au.investing.com/news/company-news/inmode-wins-court-case-against-counterfeit-sellers-93CH-3822332
Key Facts:
InMode Ltd. has secured a significant legal victory against counterfeit sellers of its Morpheus8 devices, reinforcing its commitment to consumer safety and intellectual property protection.
Court-Ordered Asset Freeze: The U.S. District Court for the Central District of California issued a preliminary injunction freezing the assets of defendants involved in selling counterfeit Morpheus8 devices, effectively halting their distribution.
CEO's Zero-Tolerance Policy: InMode's CEO, Moshe Mizrahy, emphasized the company's zero-tolerance stance on counterfeit goods, stating a commitment to public safety and the protection of consumers from unauthorized devices.
Verified Provider Program: To ensure the use of authentic products, InMode introduced a Verified Provider Program for Morpheus8 technology, allowing certified clinics to demonstrate their use of genuine InMode technology.
Financial Position: With a market capitalization nearing $1 billion and trading near its 52-week low, InMode's stock is considered potentially undervalued, presenting an opportunity for investors interested in companies with strong intellectual property protection.
Recent Earnings Report: InMode reported preliminary first-quarter revenues of $77.2 million to $77.5 million, slightly below consensus estimates. Despite this, the company maintained its full-year 2025 revenue guidance of $395 million to $405 million.
About us:
About InMode Australia
InMode Australia is a leading provider of medical aesthetic devices harnessing novel radiofrequency
("RF") and light and laser-based technologies. InMode has leveraged its medically-proven minimally invasive and non-invasive technologies to offer solutions for face and body contouring, skin
rejuvenation, anti-ageing, laser hair removal, women's health and wellness, and pigmented and
vascular lesions. We believe in providing practitioners and clinicians with the tools they need to help
people in feeling their best through real, repeatable and consistent results.
Contact details:
For more information about InMode Australia, please visit www.inmode.com.au
For PR enquiries, please contact:
Kate Boissett
Public Relations Manager - InMode ANZ
Mobile: 0422 734 621
Phone: (02) 7209 5678
Email: [email protected]
Website: www.inmode.com.au
